NKARTA INC. news, videos and press releases
For more news please use our advanced search feature.
NKARTA INC. - More news...
NKARTA INC. - More news...
- Nkarta to Participate in an April Investor Conference
- Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
- Nkarta to Participate in March Investor Conferences
- Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
- Nkarta to Participate in an Upcoming Investor Conference
- Nkarta to Participate in an Upcoming Investor Conference
- Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
- Nkarta to Participate in Upcoming Investor Conference
- Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
- Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
- Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
- Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
- Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
- Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
- Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
- Nkarta to Participate in Upcoming Investor Conferences
- Nkarta Announces Pricing of $240 Million Underwritten Offering
- Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
- Nkarta to Participate in Upcoming Investor Conferences
- Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
- Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
- Nkarta to Participate at Upcoming Investor Conferences
- Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
- Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
- Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
- Nkarta to Participate at Upcoming Investor Conference
- Nkarta Appoints Alyssa Levin Chief Financial and Business Officer
- Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
- Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
- Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
